These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 9680081)
1. Tocolytic effect of the cyclooxygenase-2 inhibitor, meloxicam: studies on uterine contractions in the rat. Yousif MH; Thulesius O J Pharm Pharmacol; 1998 Jun; 50(6):681-5. PubMed ID: 9680081 [TBL] [Abstract][Full Text] [Related]
2. Meloxicam effectively inhibits preterm labor uterine contractions in a chronically catheterized pregnant sheep model: impact on fetal blood flow and fetal-maternal physiologic parameters. Rac VE; Small C; Scott CA; Adamson SL; Rurak D; Challis JR; Lye SJ Am J Obstet Gynecol; 2006 Aug; 195(2):528-34. PubMed ID: 16626612 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800 [TBL] [Abstract][Full Text] [Related]
4. Altered fetal pituitary-adrenal function in the ovine fetus treated with RU486 and meloxicam, an inhibitor of prostaglandin synthase-II. McKeown KJ; Challis JR; Small C; Adamson L; Bocking AD; Fraser M; Rurak D; Riggs KW; Lye SJ Biol Reprod; 2000 Dec; 63(6):1899-904. PubMed ID: 11090463 [TBL] [Abstract][Full Text] [Related]
5. The effects of non-steroidal anti-inflammatory compounds on human myometrial contractility. Sawdy RJ; Sullivan MH; Bennett PR Eur J Obstet Gynecol Reprod Biol; 2003 Jul; 109(1):33-40. PubMed ID: 12818440 [TBL] [Abstract][Full Text] [Related]
6. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. Stichtenoth DO; Wagner B; Frölich JC J Investig Med; 1997 Feb; 45(2):44-9. PubMed ID: 9084574 [TBL] [Abstract][Full Text] [Related]
7. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Weber EW; Slappendel R; Durieux ME; Dirksen R; van der Heide H; Spruit M Eur J Anaesthesiol; 2003 Dec; 20(12):963-6. PubMed ID: 14690098 [TBL] [Abstract][Full Text] [Related]
9. Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes. Tsubouchi Y; Sano H; Yamada R; Hashiramoto A; Kohno M; Kusaka Y; Kondo M Eur J Pharmacol; 2000 May; 395(3):255-63. PubMed ID: 10812057 [TBL] [Abstract][Full Text] [Related]
10. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Engelhardt G; Bögel R; Schnitzler C; Utzmann R Biochem Pharmacol; 1996 Jan; 51(1):29-38. PubMed ID: 8534265 [TBL] [Abstract][Full Text] [Related]
11. Central antinociceptive effects of meloxicam on rat spinal cord in vitro. Lopez-Garcia JA; Laird JM Neuroreport; 1998 Mar; 9(4):647-51. PubMed ID: 9559932 [TBL] [Abstract][Full Text] [Related]
12. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach. Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076 [TBL] [Abstract][Full Text] [Related]
13. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers. de Meijer A; Vollaard H; de Metz M; Verbruggen B; Thomas C; Novakova I Clin Pharmacol Ther; 1999 Oct; 66(4):425-30. PubMed ID: 10546927 [TBL] [Abstract][Full Text] [Related]
14. In vitro study of tocolytic effect of rofecoxib, a specific cyclo-oxygenase 2 inhibitor. Comparison and combination with other tocolytic agents. Doret M; Mellier G; Benchaib M; Piacenza JM; Gharib C; Pasquier JC BJOG; 2002 Sep; 109(9):983-8. PubMed ID: 12269693 [TBL] [Abstract][Full Text] [Related]
15. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. van Kraaij DJ; Hovestad-Witterland AH; de Metz M; Vollaard EJ Br J Clin Pharmacol; 2002 Jun; 53(6):644-7. PubMed ID: 12047490 [TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Engelhardt G; Homma D; Schlegel K; Utzmann R; Schnitzler C Inflamm Res; 1995 Oct; 44(10):423-33. PubMed ID: 8564518 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of epoxy-eicosanoid degradation improves the tocolytic effects of indomethacin in the uterus from pregnant women. Corriveau S; Berthiaume M; Rousseau E; Pasquier JC Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):84-9. PubMed ID: 21821146 [TBL] [Abstract][Full Text] [Related]
18. In vitro study of the tocolytic effect of oroxylin A from Scutellaria baicalensis root. Shih HC; Hsu CS; Yang LL J Biomed Sci; 2009 Mar; 16(1):27. PubMed ID: 19272127 [TBL] [Abstract][Full Text] [Related]
19. Dose-dependent effects of meloxicam administration on cyclooxygenase-1 and cyclooxygenase-2 protein expression in intrauterine tissues and fetal tissues of a sheep model of preterm labor. Rac VE; Scott CA; Small C; Adamson SL; Rurak D; Challis JR; Lye SJ Reprod Sci; 2007 Dec; 14(8):750-64. PubMed ID: 18089593 [TBL] [Abstract][Full Text] [Related]
20. Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings. Engelhardt G; Bögel R; Schnitzer C; Utzmann R Biochem Pharmacol; 1996 Jan; 51(1):21-8. PubMed ID: 8534264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]